NASDAQ · Biotechnology · USD
Tenaya Therapeutics, Inc. (TNYA) Stock Analysis
Tenaya Therapeutics, Inc. (TNYA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TNYA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.41
- Previous Close
- $0.41
- Day's Range
- 0.39–0.42
- 52-Week Range
- 0.36–1.84
- Volume
- 2.16M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.88
Valuation
- Market Cap
- $87.49M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 65.54
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.52
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$90.60M
- Shares Outstanding
- 224.23M
- 1-Year Return
- −78.68%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 2.71M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, TNYA closed at $0.39, −78.68% over 1 year.
Tenaya Therapeutics, Inc. (TNYA) has a market capitalization of $87.49M.
In fiscal 2025, TNYA reported revenue of $0.00.
TNYA Stock Return by Calendar Year
Tenaya Therapeutics, Inc. (TNYA) return since Jul 2021: what $10,000 became
- 1 year
- $10,000 $2,132
- −78.68%
- 5 years
- $10,000 $189
- −98.11%
- Since Jul 2021
- $10,000 $254
- −97.46%
If you had invested $10,000 in Tenaya Therapeutics, Inc. (TNYA) at the close on July 30, 2021, the earliest close on record here, it would have been worth $254 at the close on October 21, 2026: −97.46% in total, −50.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −45.20% |
| 2025 | −50.21% |
| 2024 | −55.86% |
| 2023 | +61.19% |
| 2022 | −89.39% |
| 2021 (partial year) | +23.45% |
As of October 21, 2026.
TNYA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$90.60M | — |
| 2024 | $0.00 | −$111.13M | — |
| 2023 | $0.00 | −$124.08M | — |
| 2022 | $0.00 | −$123.67M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$93.33M | −$90.60M | — |
| 2024 | $0.00 | — | −$115.95M | −$111.13M | — |
| 2023 | $0.00 | — | −$131.19M | −$124.08M | — |
| 2022 | $0.00 | — | −$125.62M | −$123.67M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
TNYA Valuation vs Biotechnology Median
Median of 608 stocks| Metric | TNYA | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 65.54 | 13.30 | 4.9x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
SeekingAlphaTenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
YahooFDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
BenzingaTenaya Therapeutics to Participate in Upcoming September Investor Conferences
YahooTenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
SeekingAlphaTenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B